Proxima Ventures Ltd
VC Fund
Tel Aviv, Israel
Proxima Ventures Ltd is a VC fund in Tel Aviv focused on Biotechnology and Health Care. Proxima Ventures is focused on the management of investment portfolios for its customers. It offers them with financial products and consulting services. Proxima Ventures was acquired by Soluto in October 2013. Proxima Ventures was founded by Chaim Venezia and Uri Ra'anan and is based in Tel Aviv, Israel.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries Proxima Ventures Ltd invests in
Stages Proxima Ventures Ltd invests in
Countries Proxima Ventures Ltd invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Seed
- $750k–$4.5M
- Series A
- $213k–$10M
- Series B
- $10M–$150M
Investment Focus
Industry
- Biotechnology 8 (40%)
- Health Care 7 (35%)
- Therapeutics 4 (20%)
- Medical 3 (15%)
- Biopharma 3 (15%)
Stage
- Series A 7 (35%)
- Series B 6 (30%)
- Seed 3 (15%)
- Venture - Series Unknown 1 (5%)
Country
- China 6 (30%)
- United States 4 (20%)
- Israel 2 (10%)
- France 1 (5%)
- Hong Kong 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chaim Venezia
Founder and Co-executive Manager
|
Founder and Co-executive Manager | Total investments: 0 | Find email | |
Uri Ra'anan
Founder and Chief Executive Officer
|
Founder and Chief Executive Officer | Total investments: 0 | Find email | |
Zhenzhen Sun
Partner
|
Partner | Total investments: 1 | Find email | |
Zvi Margalit
Founding member
|
Founding member | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
VerImmune
|
Located in Baltimore, Maryland, VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection. This strategy utilizes a proprietary tumor-specific, tumor type agnostic, virus-inspired platform termed Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs) that redirectspre-existing pathogenic or childhood vaccine immune memory towards tumors. | $4.5M / Seed / Sep 23, 2024 | |
|
VerImmune
|
Located in Baltimore, Maryland, VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection. This strategy utilizes a proprietary tumor-specific, tumor type agnostic, virus-inspired platform termed Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs) that redirectspre-existing pathogenic or childhood vaccine immune memory towards tumors. | $3.1M / Seed / Sep 20, 2023 | |
Immune-Onc Therapeutics
|
Immune-Onc Therapeutics is a newly established bio-pharmaceutical company that focuses on developing innovative therapeutic antibodies for cancer treatment. The company applies the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients. | $25M / Series B / Jan 05, 2023 | |
|
VerImmune
|
Located in Baltimore, Maryland, VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection. This strategy utilizes a proprietary tumor-specific, tumor type agnostic, virus-inspired platform termed Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs) that redirectspre-existing pathogenic or childhood vaccine immune memory towards tumors. | $2.5M / Seed / Jul 27, 2022 | |
Yidianling
|
Yidianling is a psychological counselling platform that provides free mental health services such as free questions and answers, psychological tests, expert services, and training lectures. | $31.4M / Series B / Dec 22, 2021 | |
Great Bay Bio
|
Great Bay Bio Ltd. is a high-tech company that develops blue ocean biopharmaceuticals with a digital platform. It has a long history of biomedical research and development and rich experience in product development. Adhering to the national strategic concept of scientific and technological innovation and coordinated development of the Greater BayArea, Dawan Biotechnology brings together high-quality resources from Europe, the United States, Singapore, and Hong Kong to build a biopharmaceutical development platform centered on AI technology, big data, and Internet of Things technology, which greatly shortens The drug development cycle significantly reduces development costs and has great industry competitive advantages. | $10M / Series A / Dec 01, 2021 | |
|
Jenscare Biotech
|
A Biotech Company based In Ningbo. | Venture - Series Unknown / May 28, 2021 | |
Bioelectronica
|
Bioelectronica is a developer of digital tools intended to assist pharmaceuticals and biotechnology companies. The company's patented Hypercell technology recently won a major industry award in innovation, and offers drug developers advanced tools to do richer, more robust and faster B cell screens at a fraction of the cost. | Series A / Feb 08, 2021 | |
Singlera Genomics
|
Singlera Genomics is a fast growing company focusing on non-invasive genetic testing. Singlera’s main products and services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening, and customized scientific research services. Singlera is dedicated to the development of precisionmedicine, striving to help the patients through early, accurate and informative diagnoses. | $150M / Series B / Dec 15, 2020 | |
AccuMedical
|
AccuMedical is a full-line product company in the field of neurological intervention, headquartered in Beijing with an R&D center located in California. It develops and produces medical device products for the treatment of aneurysms, preventing, and treating bleeding diseases caused by the rupture of vascular aneurysms. | Series A / Aug 01, 2019 | |
| See all 20 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Proxima Ventures Ltd invest in?
Proxima Ventures Ltd invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 20 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Proxima Ventures Ltd's check size?
Proxima Ventures Ltd typically joins rounds of $750k–$4.5M at Seed, $213k–$10M at Series A and $10M–$150M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Proxima Ventures Ltd participates in.
How do I contact Proxima Ventures Ltd?
Public channels for Proxima Ventures Ltd include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Proxima Ventures Ltd?
The team at Proxima Ventures Ltd includes Chaim Venezia (Founder and Co-executive Manager), Uri Ra'anan (Founder and Chief Executive Officer) and Zhenzhen Sun (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
